UA100131C2 - ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ - Google Patents

ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ

Info

Publication number
UA100131C2
UA100131C2 UAA201007627A UAA201007627A UA100131C2 UA 100131 C2 UA100131 C2 UA 100131C2 UA A201007627 A UAA201007627 A UA A201007627A UA A201007627 A UAA201007627 A UA A201007627A UA 100131 C2 UA100131 C2 UA 100131C2
Authority
UA
Ukraine
Prior art keywords
receptor antagonists
oxepine
dibenzo
mineralocorticoid receptor
derived
Prior art date
Application number
UAA201007627A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Константінос Гавардінас
Прабхакар Кондаї Джадхав
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA100131(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA100131C2 publication Critical patent/UA100131C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
UAA201007627A 2007-12-19 2008-12-09 ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ UA100131C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
UA100131C2 true UA100131C2 (uk) 2012-11-26

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007627A UA100131C2 (uk) 2007-12-19 2008-12-09 ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ

Country Status (33)

Country Link
US (1) US7994164B2 (OSRAM)
EP (2) EP2235007B1 (OSRAM)
JP (1) JP5562866B2 (OSRAM)
KR (1) KR101254382B1 (OSRAM)
CN (1) CN101903377B (OSRAM)
AR (1) AR069554A1 (OSRAM)
AU (1) AU2008343524B2 (OSRAM)
BR (1) BRPI0820805A2 (OSRAM)
CA (1) CA2710409C (OSRAM)
CL (1) CL2008003600A1 (OSRAM)
CO (1) CO6300953A2 (OSRAM)
DK (1) DK2235007T3 (OSRAM)
DO (1) DOP2010000185A (OSRAM)
EA (1) EA017668B1 (OSRAM)
EC (2) ECSP10010266A (OSRAM)
ES (2) ES2459318T3 (OSRAM)
GT (1) GT201000179A (OSRAM)
HR (1) HRP20120916T1 (OSRAM)
IL (1) IL206353A (OSRAM)
MA (1) MA31910B1 (OSRAM)
MX (1) MX2010006911A (OSRAM)
MY (1) MY150474A (OSRAM)
NZ (1) NZ586300A (OSRAM)
PE (1) PE20091057A1 (OSRAM)
PL (1) PL2235007T3 (OSRAM)
PT (1) PT2235007E (OSRAM)
RS (1) RS52594B (OSRAM)
SI (1) SI2235007T1 (OSRAM)
TN (1) TN2010000292A1 (OSRAM)
TW (1) TWI431010B (OSRAM)
UA (1) UA100131C2 (OSRAM)
WO (1) WO2009085584A1 (OSRAM)
ZA (1) ZA201004257B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
BRPI1009257A2 (pt) * 2009-03-12 2016-03-08 Lilly Co Eli antagonista receptor de mineralocorticoide e métodos de uso.
ES2641144T3 (es) 2010-05-10 2017-11-07 Inserm (Institut National De La Santé Et De La Recherche Medicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
JP6263606B2 (ja) 2013-05-02 2018-01-17 ファイザー・インク Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
ES2707726T3 (es) 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
US20170246166A1 (en) * 2014-11-21 2017-08-31 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CU24569B1 (es) * 2016-09-24 2022-01-13 Kbp Biosciences Co Ltd Composición farmacéutica como antagonista del receptor de mineralocorticoides
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) * 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
CA2361734A1 (en) 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2004312293A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006015259A2 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
AU2005304560C1 (en) 2004-11-10 2013-05-09 Incyte Holdings Corporation Lactam compounds and their use as pharmaceuticals
GEP20115239B (en) 2006-10-31 2011-06-10 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptor antagonists
WO2008119918A1 (en) 2007-03-29 2008-10-09 N.V. Organon Mineralocorticoid receptor antagonists
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20100292233A1 (en) 2008-01-25 2010-11-18 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
BRPI1009257A2 (pt) 2009-03-12 2016-03-08 Lilly Co Eli antagonista receptor de mineralocorticoide e métodos de uso.

Also Published As

Publication number Publication date
KR101254382B1 (ko) 2013-04-15
DOP2010000185A (es) 2010-09-15
CA2710409C (en) 2012-11-06
DK2235007T3 (da) 2012-12-17
ES2459318T3 (es) 2014-05-09
US7994164B2 (en) 2011-08-09
RS52594B (sr) 2013-04-30
HRP20120916T1 (hr) 2012-12-31
TW200930721A (en) 2009-07-16
JP2011507868A (ja) 2011-03-10
SI2235007T1 (sl) 2013-01-31
US20090163472A1 (en) 2009-06-25
PT2235007E (pt) 2013-01-22
TN2010000292A1 (en) 2011-11-11
EA201070762A1 (ru) 2010-12-30
MA31910B1 (fr) 2010-12-01
EP2235007A1 (en) 2010-10-06
CN101903377B (zh) 2014-07-09
BRPI0820805A2 (pt) 2015-06-16
HK1144284A1 (en) 2011-02-11
NZ586300A (en) 2012-06-29
AU2008343524B2 (en) 2012-03-08
GT201000179A (es) 2012-04-16
IL206353A0 (en) 2010-12-30
IL206353A (en) 2014-06-30
TWI431010B (zh) 2014-03-21
AU2008343524A1 (en) 2009-07-09
PL2235007T3 (pl) 2013-03-29
AR069554A1 (es) 2010-02-03
MY150474A (en) 2014-01-30
ES2396605T3 (es) 2013-02-22
ECSP10010266A (es) 2010-07-30
ZA201004257B (en) 2011-11-30
EA017668B1 (ru) 2013-02-28
CN101903377A (zh) 2010-12-01
CA2710409A1 (en) 2009-07-09
CL2008003600A1 (es) 2010-02-19
JP5562866B2 (ja) 2014-07-30
PE20091057A1 (es) 2009-07-20
EP2537845B1 (en) 2014-03-19
KR20100082866A (ko) 2010-07-20
ECSP12012048A (es) 2012-08-31
WO2009085584A1 (en) 2009-07-09
EP2235007B1 (en) 2012-10-31
MX2010006911A (es) 2010-10-05
CO6300953A2 (es) 2011-07-21
EP2537845A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
TN2010000292A1 (en) 6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
MY157525A (en) Inhibitors of the renal outer medullary potassium channel
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2007133653A3 (en) Methods for treating blood disorders
WO2007092879A3 (en) Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
WO2007109783A3 (en) Substituted pyrimidine kinase inhibitors
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
WO2007121154A3 (en) Substituted benzothiazole kinase inhibitors
UA104867C2 (uk) Похідні феноксихроманкарбонової кислоти, заміщені в 6-ому положенні
SE0800742L (sv) Vikttäcke
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
BR112013009389A2 (pt) composto heterocíclico derivado de diazênio-diolato, e , composição farmacêutica
WO2006076370A3 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
EA201001828A1 (ru) Способ синтеза производных 3,6-дигидро-1,3,5-триазина
WO2009037586A3 (en) Use of peptidic vasopressin receptor agonists
MX2013010270A (es) Derivados heterociclicos diazeniodiolato de amina primaria.
SV2009002893A (es) Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida ref. prd2560
WO2007084591A3 (en) Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
WO2006120472A3 (en) Novel beta-steroid compounds
EA201001872A1 (ru) Новые способы получения производных циклопропиламида